BUZZ-Denali Therapeutics climbs after US FDA approves co's genetic disorder therapy
Reuters03-26
BUZZ-Denali <a href="https://laohu8.com/S/LENZ">Therapeutics</a> climbs after US FDA approves co's genetic disorder therapy
** Shares of Denali Therapeutics DNLI.O up 3.6% at $21.72 after the U.S. Food and Drug Administration approves co's treatment for a rare genetic disorder
** Marketed as Avlayah, the enzyme replacement therapy is aimed at treating Hunter syndrome
** Hunter syndrome is caused by lack of the iduronate‑2‑sulfatase enzyme, which leads to buildup of certain sugar molecules in the brain and the body
** Avlayah is designed to replace the missing enzyme and address underlying disease progression
** Approval marks the first regulatory clearance in the U.S. for DNLI
** Including session moves, DNLI stock up 32.4% YTD, following a 18.9% drop in 2025
(Reporting by Tharuniyaa Lakshmi in Bengaluru)
((tharuniyaa@thomsonreuters.com))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments